Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial

Scott W. Fosko, Melinda B. Chu, Eric Armbrecht, Tim Galperin, Geoffrey A. Potts, Adam Mattox, Anastasia Kurta, Kristen Polito, Jordan B. Slutsky, Nicole M. Burkemper, M. Yadira Hurley

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences